Lexilev 0,15 mg/0.03 mg FC tablets
PDF Leaflet Revision Date: 27 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Fertility control and treatment of dysfunctional uterine bleeding.
Dosage (summary)
One yellow tablet daily for 21 days, followed by one white placebo tablet for 7 days.
Special Populations
- Postpartum
- Diabetics
- Hypertensive patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may affect milk production.
Key Drug Interactions
- Anticonvulsants
- Antibiotics
- Hepatic enzyme inducers
Contraindications
- Hypersensitivity
- Breast cancer
- Thromboembolic disorders
- Severe liver disease
Common side effects
- Nausea
- Headache
- Breast tenderness
- Mood changes
Counselling Points
- Take at the same time daily
- Use barrier contraception during first cycle
- Report any severe headaches or vision changes
Serious warnings
- Increased risk of thromboembolism
- Cigarette smoking increases cardiovascular risk
Important Disclaimer
The Lexilev 0,15 mg/0.03 mg FC tablets professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
